{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:43:28Z","timestamp":1791924208506,"version":"4.3.4"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICIs) have significantly altered the treatment landscape for cancer in the last decade. However, their benefits are often offset by therapy-limiting immune-related adverse events (irAEs). Acute interstitial nephritis (AIN) is the most common renal irAE, but the exact mechanisms underlying its development are poorly understood. ICI-induced immune activation against drug-derived antigens, leading to an inflammatory response within the kidney interstitium, has been postulated, evidenced by current observations of a higher incidence of ICI-associated AIN in patients receiving AIN-inducing drugs such as proton pump inhibitors (PPIs). The role of PPIs in this specific context has garnered significant attention, given their ubiquitous use and sometimes misuse. In this issue of CKJ Miao et\u00a0al. summarise and synthesize the best available evidence to clarify the interactions of PPIs with ICIs in the development of AIN and other adverse kidney outcomes. The sum of evidence provided appear to implicate PPIs in the development of clinically significant short- and long-term kidney-related adverse effects in patients on immune checkpoint blockade, although causality cannot be proven. In this editorial we discuss the key practical implications of these findings and emphasize the need for further quality studies to delineate the true relationship of ICIs and PPIs in the development of AIN.<\/jats:p>","DOI":"10.1093\/ckj\/sfad205","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T09:10:17Z","timestamp":1692781817000},"page":"1709-1713","source":"Crossref","is-referenced-by-count":5,"title":["Proton pump inhibitors and adverse kidney outcomes during immune checkpoint blockade: time to sound the alarm?"],"prefix":"10.1093","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4899-6399","authenticated-orcid":false,"given":"Hui Zhuan","family":"Tan","sequence":"first","affiliation":[{"name":"Department of Renal Medicine, Singapore General Hospital , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1314-9675","authenticated-orcid":false,"given":"Ben","family":"Sprangers","sequence":"additional","affiliation":[{"name":"Biomedical Research Institute, Department of Immunology and Infection , UHasselt, Diepenbeek , Belgium"},{"name":"Department of Nephrology , Ziekenhuis Oost Limburg, Genk , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"key":"2023103104564754400_bib1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","article-title":"A systematic review of immune checkpoint inhibitor-associated glomerular disease","volume":"6","author":"Kitchlu","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2023103104564754400_bib2","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2215\/CJN.14671121","article-title":"Electrolyte and acid-base disorders associated with cancer immunotherapy","volume":"17","author":"Uppal","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023103104564754400_bib3","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1111\/bcp.14433","article-title":"Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy","volume":"86","author":"Mangan","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"2023103104564754400_bib4","doi-asserted-by":"crossref","first-page":"sfad109","DOI":"10.1093\/ckj\/sfad109","article-title":"Immune checkpoint inhibitors and their interaction with proton pump inhibitors-related interstitial nephritis","author":"Miao","year":"2023","journal-title":"Clin Kidney J"},{"key":"2023103104564754400_bib5","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023103104564754400_bib6","doi-asserted-by":"crossref","first-page":"e003467","DOI":"10.1136\/jitc-2021-003467","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gupta","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2023103104564754400_bib7","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1093\/ckj\/sfac109","article-title":"Risk factors associated with immune checkpoint inhibitor-induced acute kidney injury compared with other immune-related adverse events: a case\u2013control study","volume":"15","author":"G\u00e9rard","year":"2022","journal-title":"Clin Kidney J"},{"key":"2023103104564754400_bib8","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients","volume":"68","author":"Shirali","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2023103104564754400_bib9","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.ekir.2021.01.013","article-title":"Biomarkers, clinical features, and rechallenge for immune checkpoint inhibitor renal immune-related adverse events","volume":"6","author":"Isik","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2023103104564754400_bib10","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2023103104564754400_bib11","doi-asserted-by":"crossref","first-page":"1173952","DOI":"10.3389\/fimmu.2023.1173952","article-title":"Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"2023103104564754400_bib12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.ajkd.2021.05.012","article-title":"Incidence and predictors of CKD and estimated GFR decline in patients receiving immune checkpoint inhibitors","volume":"79","author":"Chute","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"2023103104564754400_bib13","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s41581-022-00630-8","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury","volume":"18","author":"Sprangers","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"2023103104564754400_bib14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12882-018-0848-y","article-title":"Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report","volume":"19","author":"Koda","year":"2018","journal-title":"BMC Nephrol"},{"key":"2023103104564754400_bib15","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0140-6736(94)91945-3","article-title":"Recurrent acute interstitial nephritis on rechallenge with omeprazole","volume":"344","author":"Assouad","year":"1994","journal-title":"Lancet"},{"key":"2023103104564754400_bib16","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/ckj\/sfaa027","article-title":"Acute tubulointerstitial nephritis induced by checkpoint inhibitors versus classical acute tubulointerstitial nephritis: are they the same disease?","volume":"14","author":"Draibe","year":"2021","journal-title":"Clin Kidney J"},{"key":"2023103104564754400_bib17","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/j.ekir.2020.08.002","article-title":"Hyperacute onset of Immune checkpoint inhibitor-related acute interstitial nephritis","volume":"5","author":"Tawhari","year":"2020","journal-title":"Kidney Int Rep"},{"key":"2023103104564754400_bib18","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"2023103104564754400_bib19","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1681\/ASN.2007111179","article-title":"CXCL9, but not CXCL10, promotes CXCR3-dependent immune-mediated kidney disease","volume":"19","author":"Menke","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"2023103104564754400_bib20","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1111\/ajt.12426","article-title":"Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury","volume":"13","author":"Hricik","year":"2013","journal-title":"Am J Transplant"},{"key":"2023103104564754400_bib21","first-page":"e165108","article-title":"Tertiary lymphoid structure signatures are associated with immune checkpoint inhibitor related acute interstitial nephritis","volume-title":"JCI Insight","author":"Singh","year":"2022"},{"key":"2023103104564754400_bib22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.medj.2022.12.007","article-title":"Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors","volume":"4","author":"Nu\u00f1ez","year":"2023","journal-title":"Med"},{"key":"2023103104564754400_bib23","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.2215\/CJN.00920121","article-title":"Gene expression profiling in kidney transplants with immune checkpoint inhibitor-associated adverse events","volume":"16","author":"Adam","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023103104564754400_bib24","doi-asserted-by":"crossref","first-page":"e168950","DOI":"10.1172\/JCI168950","article-title":"Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis","volume":"133","author":"Moledina","year":"2023","journal-title":"J Clin Invest"},{"key":"2023103104564754400_bib25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience","volume":"7","author":"Mamlouk","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2023103104564754400_bib26","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2021.12.247","article-title":"AGA clinical practice update on de-prescribing of proton pump inhibitors: expert review","volume":"162","author":"Targownik","year":"2022","journal-title":"Gastroenterology"},{"key":"2023103104564754400_bib27","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1053\/j.ajkd.2019.07.012","article-title":"Proton pump inhibitors and the kidney: implications of current evidence for clinical practice and when and how to deprescribe","volume":"75","author":"Al-Aly","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2023103104564754400_bib28","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1200\/JOP.2017.026666","article-title":"Oncology pharmacist opportunities: closing the gap in quality care","volume":"14","author":"Vulaj","year":"2018","journal-title":"J Oncol Pract"},{"key":"2023103104564754400_bib29","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/ki.1989.78","article-title":"Study of the immunopathogenesis of tubulointerstitial nephritis using model systems","volume":"35","author":"Wilson","year":"1989","journal-title":"Kidney Int"},{"key":"2023103104564754400_bib30","doi-asserted-by":"crossref","first-page":"799","DOI":"10.34067\/KID.0003962021","article-title":"Is rechallenge appropriate in patients that develop immune checkpoint inhibitor-associated AKI?: PRO","volume":"3","author":"Herrmann","year":"2022","journal-title":"Kidney360"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfad205\/51408234\/sfad205.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/16\/11\/1709\/52691918\/sfad205.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/16\/11\/1709\/52691918\/sfad205.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T02:37:02Z","timestamp":1698719822000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/16\/11\/1709\/7258653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":30,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,9,1]]},"published-print":{"date-parts":[[2023,10,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfad205","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,9,1]]}}}